Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
Dualyx has raised $43.5M in total funding. The most recent round was Series A. The last funding was announced in May 2023.
Dualyx's investors include HTGF (High-Tech Gruenderfonds), Andera Partners, Fountain Healthcare Partners, Forbion Capital Partners, BioGeneration Ventures.
Dualyx is headquartered in Ghent, Belgium.
Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
Dualyx is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dualyx — Funding & Investors." VCBacked, May 15, 2023, https://www.vcbacked.co/company/dualyx. Accessed August 14, 2026.
VCBacked. (2023). Dualyx — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/dualyx
{{cite web |title=Dualyx — Funding & Investors |url=https://www.vcbacked.co/company/dualyx |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated